A
This company develops next-generation immunotherapies by harnessing bispecific antibody innovation to precisely steer and ignite immune responses against cancer and autoimmune diseases. They focus on redirecting and reawakening the patient’s immune response using specialized immune cell subsets and selective tumor antigens. Their robust pipeline aims to deliver best-in-class treatments for solid tumors and autoimmune conditions with significant unmet medical needs.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This company develops next-generation immunotherapies by harnessing bispecific antibody innovation to precisely steer and ignite immune responses. They redirect and reawaken the patient’s immune response by leveraging specialized immune cell subsets and highly selective tumor antigens. The resulting pipeline aims to deliver best-in-class therapies for solid tumors and autoimmune diseases with significant unmet need.